Dec 16, 2024
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761
Dec 15, 2024
Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II
Dec 11, 2024
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
Dec 09, 2024
Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Nov 14, 2024
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting
Oct 28, 2024
Immutep Quarterly Activities Report Q1 FY25
Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024
Oct 17, 2024
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
Oct 10, 2024
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
Oct 03, 2024
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
Sep 24, 2024
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
Sep 17, 2024
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Sep 15, 2024
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
Aug 20, 2024
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
